LY3295668
- Generic Name
- LY3295668
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26ClF2N5O2
- CAS Number
- 1919888-06-4
- Unique Ingredient Identifier
- 1WX8O5XV4R
- Associated Conditions
- -
- Associated Therapies
- -
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05017025
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of AK-01 (LY3295668) in Solid Tumors
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT03092934
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦McGill University, Montreal, Quebec, Canada
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath